Relief Therapeutics Holding AG (RLFTF)

[TraderInvictus]

We are stuck at .59 because that puts the company at a 1.42billion valuation. We should soon see consolidation level out at .65 a share. Putting the company at a 1.5billion dollar valuation. A fair market value of an unproven COVID-19 drug. Once approved, the valuation should adjust accordingly from there. Since we are in an interesting realm with no benchmark to compare a successful covid-19 treatment, it’s hard to put a concrete number out in value. Do you factor in just anticipated sales revenue? Do you factor in societal value for returning the economy back to normal? Speculatively, this stock could only be worth about 1.00 on sales revenue alone if they do not up charge over current treatment cost of aviptadil. But, do you then factor in how much more this treatment could be worth and valued for other pulmonary and neurological treatments?

An interesting fact that I’ve yet to be seen brought up here is aviptadils effect on grey matter regeneration within the brain. This drug under the Shoemaker protocol was used as a treatment for atrophy in grey matter when used to treat chronic inflammatory response syndrome for those exposed to environmental toxins such as mold.

“CIRS has been found to be the underlying (treatable) cause of some unusual cases of multiple sclerosis, idiopathic juvenile arthritis, interstitial lung disease and other illnesses. “

So if you follow that rabbit hole of ideology and search. Some forms of autism and or multiple sclerosis may be caused by or exacerbated by neurotoxins from environmental exposure. VIP in its early stages of testing was shown to cleanse the body of such toxins. But I’m getting way ahead of myself and off topic here. If one starts traveling off the tangent of COVID-19 on this board, it turns into a debate for some odd reason by those that can’t see more than 5 minutes into a developmental pipeline.


COVID-19 is just a gateway into exactly what this drug can do. So while people fret over the day to day price fluctuations, if you look past the COVID-19 pandemic into a year or more down the road when Dr. Javitt has more capital to expand research into aviptadil, well we are early shareholders in something truly amazing. As Javitt is a hugely intellectual being and has the foresight to look past the today and plan for the tomorrow.

https://www.yoursolutioncompounding.com.au/pages/cirs-chronic-inflammatory-response-syndrome

Some light reading in that link.